Shri Shivraj Singh Chouhan to dedicate India's First Indigenous H5N1 (Clade 2.3.2.1a) Chicken Vaccine to the Nation on 20 November
Published: · Updated:
Source: PIB (Press Information Bureau) · Read the original ↗
Summary
- Union Agriculture Minister Shivraj Singh Chouhan will dedicate India's first indigenous inactivated H5N1 (Clade 2.3.2.1a) HPAI vaccine for chickens to the nation on 20 Nov 2026 at ICAR-NIHSAD, Bhopal.
- The vaccine was developed by ICAR-NIHSAD. It is described as the first of its kind in India against this clade.
- No specific commercial vaccine is currently available for Clade 2.3.2.1a, which makes the indigenous development significant.
Key facts for Prelims
- Vaccine: inactivated H5N1 (Clade 2.3.2.1a) HPAI vaccine for chickens, India's first indigenous one. It was developed by ICAR-NIHSAD, Bhopal, and will be dedicated to the nation on 20 Nov 2026.
- ICAR-NIHSAD is in Bhopal, Madhya Pradesh, under ICAR (Ministry of Agriculture & Farmers' Welfare). HPAI is commonly called bird flu.
- H5N1 and H5N8 are subtypes responsible for Indian outbreaks. H5N1 Clade 2.3.2.1a is the clade responsible for most outbreaks in chickens, and no specific commercial vaccine existed for it.
- WHO is the source for global human-case counts.
- Minister: Shivraj Singh Chouhan, Union Minister of Agriculture and Farmers Welfare and Rural Development.
Data and details
- HPAI outbreaks can cause nearly 100% mortality in infected birds. Large-scale culling and trade restrictions cause heavy losses.
- First detection in India: 2006. Since then, more than 500 combined outbreaks of H5N1 and H5N8.
- A major outbreak could cut India's GDP growth by up to 1.5%. More than 20% of the poultry population could be at risk if the disease spreads uncontrolled.
- The 2006 outbreak caused estimated direct and indirect losses of Rs 2,200–3,000 crore. An outbreak in Manipur caused losses equal to 0.5% of the state's GDP.
- WHO: 1,003 human H5N1 cases, including 479 deaths, across 25 countries including India, since 2003.
- Clade 2.3.2.1a infections have recently been detected in mammals and in three human cases.
- Impact beyond farms: the article says the disease can affect global trade, prices of poultry products and farmers' livelihoods. It adds that the vaccine aims to protect against Clade 2.3.2.1a H5N1 strains circulating in India.
- Not stated in the article: efficacy or trial data, regulatory approval or licensing status, production and rollout plan, or changes to India's outbreak-control policy.
Static–dynamic linkage
- Zoonotic diseases cross between animals and humans. Poultry vaccination reduces viral circulation, economic losses and spillover risk to mammals and people.
- Avian influenza (bird flu) is a viral disease of birds. The subtype name (H5N1) refers to two surface proteins, haemagglutinin type 5 and neuraminidase type 1. Clades are evolutionary lineages of the virus. Matching a vaccine to the circulating clade is key to protection.
- The static concept is disease control by vaccination versus culling, the One Health approach, and the economic importance of poultry.
Syllabus mapping: GS3 – S&T: biotechnology and indigenisation of technology | GS3 – Agriculture: animal husbandry, poultry economics | GS2 – Health: zoonoses and One Health
Background primer
ICAR-National Institute of High Security Animal Diseases (NIHSAD), Bhopal
- What it is:
- A premier ICAR institute for research on exotic and emerging animal pathogens, including zoonoses. It functions under ICAR, Ministry of Agriculture & Farmers' Welfare.
- Founded:
- It became an independent ICAR institute on 8 Aug 2014, from its earlier status as the High Security Animal Disease Laboratory (HSADL), a regional station of IVRI Izatnagar. The HSADL was born in 1998 and its bio-containment laboratory was dedicated to the nation on 23 June 2000. Secondary sources give conflicting earlier dates, so the exact origin year is not fully confirmed.
- Mandate:
- Basic and strategic research on exotic, emerging and re-emerging animal diseases, and biorisk management and capacity building in biosafety, biosecurity and bio-containment.
- Why it matters:
- Safe handling of dangerous animal pathogens, early detection of threats at the human–animal interface and emergency preparedness with diagnostics and vaccines.
Highly Pathogenic Avian Influenza (HPAI) / H5N1
- What it is:
- A highly contagious viral disease of birds. H5N1 HPAI was first identified in domestic waterfowl in southern China in 1996.
Additional context
- Earlier lead: In Dec 2022, ICAR-NIHSAD's inactivated low-pathogenic avian influenza (H9N2) vaccine for chickens was transferred to industry (M/s Globion India Pvt. Ltd.) through Agrinnovate India Ltd. It was described as the first indigenous H9N2 vaccine.
- Related technologies: NIHSAD scientists have released an indirect ELISA kit for sero-diagnosis of avian influenza and a multiplex real-time RT-PCR kit for avian influenza A typing and differentiation of H5 and H9 subtypes.
- Origin of the avian influenza capacity: An SPF (Specific Pathogen Free) unit was established at NIHSAD's Bhopal campus in 2008, funded by a special ICAR grant after India's first HPAI H5N1 bird flu outbreak in 2006.
- Policy framing: In July 2024 the Department of Animal Husbandry & Dairying convened a high-level brainstorming session on avian influenza surveillance and vaccination under the One Health approach, with presentations from the human health, animal husbandry and wildlife sectors.
Mains dimensions
- Economic stakes: Poultry outbreaks cause near-total flock mortality, culling, trade restrictions and farmer losses. The 2006 and Manipur examples, the 1.5% GDP-growth sensitivity and the 20% poultry-at-risk figure show systemic risk.
- Public health and One Health: Spillover of Clade 2.3.2.1a to mammals and three human cases, against 479 deaths in 1,003 human cases globally, makes poultry control a public-health measure. This links animal health, human health and the environment.
- Atmanirbharta in biotech: No commercial vaccine for this clade existed, so an indigenous product reduces dependence on imports and can be matched to circulating strains.
- Institutional capacity: The vaccine comes from a public-sector ICAR laboratory with a BSL-3/ABSL-4 design, showing the role of public research institutes. Commercialisation and technology transfer to private manufacturers will decide impact.
- Challenges: Vaccination may affect trade status and disease surveillance, and it needs strong biosecurity, a cold chain and extension services. Equitable access for small and backyard poultry farmers also matters.
- Way forward: Rapid licensing and scale-up, integrated surveillance across veterinary and human-health agencies, farmer compensation and awareness, and international standards compliance.
Possible Mains question
**GS3 (S&T/Agriculture), 10 marks:** "India has developed its first indigenous vaccine for H5N1 avian influenza in chickens. Discuss the economic and public-health significance of controlling avian influenza and the One Health approach."
Related topics
- Zoonoses and pandemic preparedness (One Health, WHO)
- Animal Husbandry and Dairying: livestock disease control schemes, National Animal Disease Control Programme
- ICAR and agricultural research system
- Vaccine types: inactivated, live-attenuated, mRNA; clade/subtype nomenclature
- Biosafety levels (BSL-1 to BSL-4) and biosecurity
Topics: GS3
All current affairs of 18 November 2026 → · UPSC Current Affairs